CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Assertio Holdings, Inc. (NASDAQ: ASRT) Investors to Inquire About a Securities Fraud Class Action by March 5, 2024

PHILADELPHIA, March 4, 2024 /PRNewswire/ -- Nationally recognized law firm, Berger Montague PC, informs investors that a lawsuit was filed against Assertio Holdings, Inc. ("Assertio") (NASDAQ: ASRT) on behalf of purchasers of Assertio's securities between March 9, 2023 and November 8, 2023, inclusive (the "Class Period").

Investors that suffered losses from Assertio Holdings, Inc. (NASDAQ: ASRT) investments can follow the link below for more information regarding the lawsuit:

CLICK HERE to learn more about the lawsuit.

Investors who purchased or acquired Assertio securities during the Class Period may, no later than March 5, 2024, seek to be appointed as a lead plaintiff representative of the class. 

The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Assertio's reliance on Indocin products to boost its net income was unsustainable given the risk of generic competition; (ii) Assertio's acquisition of Spectrum Pharmaceuticals, Inc. ("Spectrum Acquisition") was less valuable than Assertio had represented to investors; and (iii) accordingly, Assertio had overstated the positive impact the sale of Indocin products and the Spectrum Acquisition were likely to have on Assertio's profitability.

According to the lawsuit, the truth about Assertio's prospects was finally revealed on November 8, 2023, when Assertio issued a press release announcing its Q3 2023 financial results. Among other results, Assertio reported Q3 non-GAAP earnings-per-share of $0.01, missing consensus estimates by $0.09, and revenue of $35.63 million, missing consensus estimates by $14.8 million. In addition, the press release stated, in part, "Our third quarter results were disappointing, with the loss of Indocin exclusivity and Rolvedon results below expectations driving significant charges to our net income."

Following this news, Assertio's stock price fell $0.92 per share, or 43.19%, to close at $1.21 per share on November 9, 2023.

For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at [email protected] or (267) 637-3176, or Andrew Abramowitz at [email protected] or (215) 875-3015 or CLICK HERE. 

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts:
James Maro, Senior Counsel
Berger Montague
(267) 637-3176
[email protected]

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected] 

SOURCE Berger Montague